NASDAQ$ISRG
Intuitive Surgical Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Intuitive Surgical's Q4 2024 earnings reflected strong growth in revenue and system placements.
Intuitive Surgical announced strong financial results for the fourth quarter of 2024, with revenue increasing by 25% compared to the fourth quarter of 2023. The company placed 493 da Vinci surgical systems during the quarter, including 174 da Vinci 5 systems. GAAP net income attributable to Intuitive Surgical was $686 million, or $1.88 per diluted share, while non-GAAP net income was $805 million, or $2.21 per diluted share.
- Worldwide da Vinci procedures grew approximately 18% compared with the fourth quarter of 2023.
- The Company placed 493 da Vinci surgical systems, compared with 415 in the fourth quarter of 2023.
- Fourth quarter 2024 revenue of $2.41 billion increased 25% compared with $1.93 billion in the fourth quarter of 2023.
- Fourth quarter 2024 GAAP net income attributable to Intuitive Surgical, Inc. was $686 million, or $1.88 per diluted share.
Headline financials
Revenue & EPS history
Intuitive Surgical · Revenue · Quarterly
$2.41B
Revenue by segment
Intuitive Surgical · $1.74B total across 3 segments · Q3 2023
- Instruments and accessories$1.07B+22.9%61.4%
- Systems$379M-10.9%21.8%
- Services$293M+12.7%16.8%
Forward guidance
The Company expects worldwide da Vinci procedures to increase approximately 13% to 16% in 2025 as compared to 2024. The Company expects non-GAAP gross profit margin to be within a range of 67% and 68% of net revenue in 2025, compared to 69.1% in 2024. The Company expects non-GAAP operating expense growth to be within a range of 10% to 15% in 2025, compared to 10% in 2024.
Tailwinds
- Worldwide da Vinci procedures to increase approximately 13% to 16% in 2025
- Strong revenue growth driven by da Vinci procedure volume
- Increase in the installed base of systems
- Continued innovation with da Vinci 5 systems
- Expected non-GAAP gross profit margin between 67% and 68%
Headwinds
- Potential impact of new tariffs on business
- Macroeconomic environment may impact customer spending
- Disruptions to the Company’s supply chain
- Delays in obtaining new product approvals
- Changes in hospital admissions and actions by payers
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
+1.9%
Avg return
Earnings day
+1.3%
Avg return
5 days after
+3.1%
Avg return
30 days after
55%
40 / 73 earnings
Positive
+31.1%
Q2 2009
Best reaction
-16.7%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.8% | -3.5% | -9.3% | |
| Q4 2025 | -3.1% | +4.4% | -2.8% | |
| Q3 2025 | -2.3% | +19.1% | +21.4% | |
| Q2 2025 | +0.7% | +0.7% | -5.7% | |
| Q1 2025 | +1.9% | +7.4% | +12.7% | |
| Q4 2024 | -4.0% | +4.1% | +2.7% | |
| Q3 2024 | +9.3% | +8.6% | +10.7% | |
| Q2 2024 | +6.8% | +6.8% | +12.4% | |
| Q1 2024 | -2.1% | +0.8% | +6.6% | |
| Q4 2023 | -1.5% | +10.6% | +17.7% | |
| Q3 2023 | -3.1% | +0.7% | +10.8% | |
| Q2 2023 | -3.7% | -5.4% | -18.2% | |
| Q1 2023 | +11.0% | +11.7% | +16.1% | |
| Q4 2022 | -4.8% | -4.6% | -9.6% | |
| Q3 2022 | +11.1% | +14.9% | +37.2% | |
| Q2 2022 | -3.4% | -1.1% | +2.5% | |
| Q1 2022 | -16.7% | -19.3% | -27.7% | |
| Q4 2021 | -8.2% | -6.2% | -13.7% | |
| Q3 2021 | +2.3% | +2.8% | +8.1% | |
| Q2 2021 | +1.4% | +4.7% | +13.2% | |
| Q1 2021 | +9.9% | +7.9% | +2.6% | |
| Q4 2020 | -6.8% | -1.3% | +2.5% | |
| Q3 2020 | +0.2% | -2.4% | +0.3% | |
| Q2 2020 | +2.1% | +1.2% | +3.8% | |
| Q1 2020 | +3.0% | -2.8% | +1.8% | |
| Q4 2019 | -3.4% | -6.6% | +0.5% | |
| Q3 2019 | +6.8% | +1.0% | +7.4% | |
| Q2 2019 | +1.0% | +2.7% | -5.4% | |
| Q1 2019 | -6.5% | -4.7% | -6.6% | |
| Q4 2018 | -2.8% | -6.7% | +4.1% | |
| Q3 2018 | -7.1% | -6.6% | -4.5% | |
| Q2 2018 | -2.1% | -0.9% | -0.6% | |
| Q1 2018 | +12.6% | +9.1% | +9.5% | |
| Q4 2017 | +0.6% | -2.2% | -2.3% | |
| Q3 2017 | +4.3% | +4.8% | +10.8% | |
| Q2 2017 | -4.1% | -2.3% | +1.8% | |
| Q1 2017 | +5.1% | +5.9% | +11.9% | |
| Q4 2016 | +6.9% | +0.4% | +6.5% | |
| Q3 2016 | -4.0% | -4.4% | -7.7% | |
| Q2 2016 | +4.9% | +2.8% | +2.2% | |
| Q1 2016 | +2.8% | — | — | |
| Q4 2015 | +2.1% | — | — | |
| Q3 2015 | +4.4% | — | — | |
| Q2 2015 | +10.5% | — | — | |
| Q1 2015 | -6.5% | — | — | |
| Q4 2014 | -0.1% | — | — | |
| Q3 2014 | -0.7% | — | — | |
| Q2 2014 | +18.8% | — | — | |
| Q1 2014 | -9.0% | — | — | |
| Q4 2013 | -6.5% | — | — | |
| Q3 2013 | -6.2% | — | — | |
| Q2 2013 | -5.5% | — | — | |
| Q1 2013 | -4.5% | — | — | |
| Q4 2012 | +11.6% | — | — | |
| Q3 2012 | +3.9% | — | — | |
| Q2 2012 | -9.3% | — | — | |
| Q1 2012 | +8.0% | — | — | |
| Q4 2011 | +0.4% | — | — | |
| Q3 2011 | +9.3% | — | — | |
| Q2 2011 | +10.3% | — | — | |
| Q1 2011 | +2.0% | — | — | |
| Q4 2010 | +1.5% | — | — | |
| Q1 2009 | +1.5% | — | — | |
| Q3 2010 | -7.9% | — | — | |
| Q2 2010 | +7.4% | — | — | |
| Q1 2010 | +0.2% | — | — | |
| Q4 2007 | -1.9% | — | — | |
| Q4 2009 | -1.9% | — | — | |
| Q3 2009 | -3.1% | — | — | |
| Q3 2008 | -3.1% | — | — | |
| Q2 2008 | +31.1% | — | — | |
| Q4 2008 | +31.1% | — | — | |
| Q2 2009 | +31.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro